结外 NK/T 细胞淋巴瘤 (ENKTCL) 是一种非霍奇金淋巴瘤，以其对鼻结构的局部破坏性影响和炎症细胞因子的全身诱导而闻名。放射治疗和非蒽环类化疗的同时治疗提高了局部疾病阶段患者的生存率。然而，晚期和复发或难治性 (R/R) 病例的生存结果差异很大。因此，我们使用随机效应模型进行荟萃分析，以评估晚期或 R/R ENKTCL 的预后因素，并使用数字提取器由于缺乏针对这些患者的已发表的前瞻性试验，因此绘制了 Kaplan-Meier 图。我们观察到，接受门冬酰胺酶治疗的晚期 ENKTCL 患者的中位无进展生存期 (PFS) 为 14.3 个月，总生存期 (OS) 为 19 个月。在 R/R ENKTCL 中，PFS 和 OS 分别为 11.7 个月和 15.6 个月。此外，天冬酰胺酶组的晚期 ENKTCL 的 OS 结局优于非天冬酰胺酶组，其中 PEG-天冬酰胺酶的结果优于使用门冬酰胺酶的结果。治疗前血流中的 Epstein-Barr 病毒 (EBV)-DNA 阳性与晚期 ENKTCL 的不良预后相关，并且在 R/R ENKTCL 和治疗后 EBV 病毒血症患者中观察到类似的趋势。总的来说，这些发现表明使用门冬酰胺酶或 PEG-门冬酰胺酶进行化疗可以提高晚期或 R/R ENKTCL 的生存率。然而，未来必须制定策略来有效抑制 EBV 病毒血症并实现根除肿瘤的深度反应。版权所有 © 2024 Kim、Kim、Han、Min、Jeon 和 Cho。

Extranodal NK/T-cell lymphoma (ENKTCL), a non-Hodgkin lymphoma, is known for its destructive local impact on nasal structures and systemic induction of inflammatory cytokines. Concurrent treatment with radiation and nonanthracycline- based chemotherapy has improved survival rates in patients with localized disease stages. However, survival outcomes vary significantly in advanced-stage and relapsed or refractory (R/R) cases.Therefore, we conducted a meta-analysis using random effects models to assess prognostic factors in advanced or R/R ENKTCL, employing a digital extractor on Kaplan-Meier graphs owing to the scarcity of published prospective trials for these patients.We observed that patients with advanced ENKTCL treated with Lasparaginase had a median progression-free survival (PFS) of 14.3 months and an overall survival (OS) of 19 months. In R/R ENKTCL, PFS and OS were 11.7 and 15.6 months, respectively. Additionally, OS outcomes in advanced-stage ENKTCL were better in the asparaginase group than that in the non-asparaginase group, with PEG-asparaginase showing superior results compared with that using Lasparaginase. Epstein-Barr Virus (EBV)-DNA positivity in the bloodstream prior to treatment was associated with poor outcomes in advanced-stage ENKTCL, and similar trends were observed in patients with R/R ENKTCL and post-treatment EBV viremia.Collectively, these findings suggest that chemotherapy with Lasparaginase or PEG-asparaginase can enhance survival in advanced or R/R ENKTCL. However, future strategies must be developed to effectively suppress EBV viremia and achieve a deep response toward tumor eradication.Copyright © 2024 Kim, Kim, Han, Min, Jeon and Cho.